Nashville-based integrated research and technology platform company, ObjectiveHealth, has announced a clinical research partnership with Urology of St. Louis. Together, they have established a joint clinical research centre called Specialty Clinical Research of St. Louis, which aims to provide access to advanced diagnostic tools, treatments, and therapies to enhance health outcomes in urologic diseases.
Urology of St. Louis, with 27 practising urology associates at 21 locations, will focus on population-intensive urological disorders, including benign prostatic hypertrophy, kidney stone disease, urinary tract infections, overactive bladder, bladder cancer, and prostate cancer. The research will cover interventional cancer trials and predictive biomarkers in precision medicine diagnostics. ObjectiveHealth, operating in 31 locations across 16 states, offers clinical research in various therapeutic areas, enabling physicians to expand their practices and enhance patient care.
This partnership aims to contribute to the advancement of urological disease research and improve the standard of care for affected individuals. Urology St. Louis recognizes the importance of clinical research in uncovering new insights and treatments to benefit patients with urological diseases.
Click here to read the original news story.